|Articles|February 1, 2001

Emerging Strategies in the Treatment of Gastroesophageal Reflux Disease
Volume 7
Issue 1 Suppl

How Far to Go? Screening and Surveillance in Barrett's Esophagus

Author(s)David A. Lieberman, MD, Richard E. Sampliner, MD

Download PDF: How Far to Go? Screening and Surveillance in Barrett's Esophagus

Articles in this issue

over 25 years ago

Article

Participating Faculty

over 25 years ago

Article

Introduction

over 25 years ago

Article

Beyond Heartburn: Extraesophageal Manifestations of Gastroesophageal Reflux Disease

over 25 years ago

Article

The Impact of Nonsteroidal Anti-Inflammatory Drug-Induces Gastropathy

over 25 years ago

Article

Aggressive Acid Control: Minimizing Progression of Barrett's Esophagus

over 25 years ago

Article

Debating the Role of Helicobacter pylori Infection

over 25 years ago

Article

Continuing Medical Education Quiz

over 25 years ago

Article

Selected Abstracts

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

How Far to Go? Screening and Surveillance in Barrett's Esophagus

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Rewriting the AML Treatment Playbook: Tina Bhatnagar, DO

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

How Far to Go? Screening and Surveillance in Barrett's Esophagus

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Rewriting the AML Treatment Playbook: Tina Bhatnagar, DO